miércoles, 21 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· December 23, 2025

HKIC ends year on high note but Hong Kong cost of living a drawback for attracting talent

View original at finance.yahoo.com
HKIC ends year on high note but Hong Kong cost of living a drawback for attracting talent The success of the government's Hong Kong Investment Corporation (HKIC) in establishing an ecosystem for start-ups to raise funds has put a damper on the Christmas plans for employees of some local venture capital (VC) firms…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • HKIC has a dual mandate: to generate reasonable returns and enhance the long-term competitiveness and economic vitality of Hong Kong

    80% confidence
  • The sector is now entering a spring-like phase of growth, making this the perfect time for HKIC to establish robust ecosystem

    80% confidence
  • Hong Kong's rent and living costs are very expensive by international standards, discouraging startup talent from relocating because their income may not be enough

    80% confidence
  • Government should provide affordable housing to make it easier for talent to live in Hong Kong as talent is important for developing innovation industry

    80% confidence
  • Being a second or third-mover is not necessarily disadvantageous as Hong Kong can learn from mistakes of others

    80% confidence
  • Hong Kong's high cost of living makes it difficult to attract talent needed to work in Hong Kong

    80% confidence
  • Some MindWorks staff will not have Christmas holidays to focus on closing numerous ongoing deals

    80% confidence
  • One of HKIC's key priorities is to channel market capital into high-potential, nascent-stage industries and attract innovative enterprises to Hong Kong

    80% confidence
  • HKIC investment is an endorsement giving confidence to partner with other investees without needing to do due diligence again

    80% confidence
  • 2025 was one of the busiest years for MindWorks since its establishment 11 years ago

    80% confidence
  • HKIC has invested in over 150 projects, leveraging more than HK$6 of private capital for every Hong Kong dollar it invested

    80% confidence
  • Teaming up with HKIC makes it easier to negotiate investment deals

    80% confidence
  • HKIC and Temasek are different because Singapore sovereign focuses on profits while HKIC looks for projects to promote Hong Kong's innovative industries

    80% confidence
  • AI, logistics, and longevity would be key growth drivers for Hong Kong's investment ecosystem in coming years

    80% confidence
  • The startup investment market experienced severe downturn during pandemic and only rebounded over past two years

    80% confidence
  • After partnering with HKIC, the number of deals MindWorks is working on tripled compared to last year

    80% confidence
  • HKIC is establishing an ecosystem for the innovative industry in Hong Kong, not only providing funding but also emphasizing establishing industry networks

    80% confidence
  • HKIC investment has effectively turned Soy-Sky into a government-backed company, which is important when pitching to Belt and Road countries

    80% confidence
  • Remuneration for startup talent is much higher in mainland China and the US where markets are much bigger and more competitive

    80% confidence
  • The partnership between HKIC and BioMap is a very important endorsement that helped get funding from other investors

    80% confidence
  • MindWorks shares the same mission with HKIC which extends beyond seeking financial returns to fostering a robust ecosystem for innovative industries in Greater Bay Area

    80% confidence

Citado en estos reportajes de Via News

Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Q4 2026 Biopharma Catalyst Crunch: Late-Stage Readouts and Regulatory Milestones Converge on the Ivonescimab PDUFA Date
October 2026 is dense with clinical and regulatory news. Phase 3 trials hit primary endpoints (ALOFT-IPF, RESTORE-3), long-term data came out (MIUDELLA at 6 years, QUILT-3.032), and the FDA accepted Roche's vamikibart BLA. Scholar Rock resubmitted its apitegromab MAA to the EMA. The next catalysts are ESMO 2026 (Oct 23) and the Nov 14 FDA PDUFA date for ivonescimab, followed by Maritime-1 primary completion in January 2027. The speculative QAIAx items (QIII pilot, microcities patent) are a weak, tangential thread with little financial substance.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,406 documentos fuente archivados
Consulta estos datos → isubstrate.com